290 related articles for article (PubMed ID: 15555741)
1. New oral delivery systems for treatment of inflammatory bowel disease.
Friend DR
Adv Drug Deliv Rev; 2005 Jan; 57(2):247-65. PubMed ID: 15555741
[TBL] [Abstract][Full Text] [Related]
2. Pharmaceutical approaches to colon targeted drug delivery systems.
Chourasia MK; Jain SK
J Pharm Pharm Sci; 2003; 6(1):33-66. PubMed ID: 12753729
[TBL] [Abstract][Full Text] [Related]
3. Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease.
Klotz U; Schwab M
Adv Drug Deliv Rev; 2005 Jan; 57(2):267-79. PubMed ID: 15555742
[TBL] [Abstract][Full Text] [Related]
4. Novel drug delivery strategies for the treatment of inflammatory bowel disease.
Kesisoglou F; Zimmermann EM
Expert Opin Drug Deliv; 2005 May; 2(3):451-63. PubMed ID: 16296767
[TBL] [Abstract][Full Text] [Related]
5. TARGIT technology: coated starch capsules for site-specific drug delivery into the lower gastrointestinal tract.
Watts P; Smith A
Expert Opin Drug Deliv; 2005 Jan; 2(1):159-67. PubMed ID: 16296742
[TBL] [Abstract][Full Text] [Related]
6. [New systems for colonic drug targeting].
Janovská L; Vetchý D; Rabisková M
Ceska Slov Farm; 2006 Sep; 55(5):203-9. PubMed ID: 17128589
[TBL] [Abstract][Full Text] [Related]
7. Mesalamine delivery systems: do they really make much difference?
Qureshi AI; Cohen RD
Adv Drug Deliv Rev; 2005 Jan; 57(2):281-302. PubMed ID: 15555743
[TBL] [Abstract][Full Text] [Related]
8. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
9. Oral colon targeted delivery systems for treatment of inflammatory bowel diseases: synthesis, in vitro and in vivo assessment.
El-Kamel AH; Abdel-Aziz AA; Fatani AJ; El-Subbagh HI
Int J Pharm; 2008 Jun; 358(1-2):248-55. PubMed ID: 18502065
[TBL] [Abstract][Full Text] [Related]
10. Multiparticulate systems containing 5-aminosalicylic acid for the treatment of inflammatory bowel disease.
Bautzová T; Rabišková M; Lamprecht A
Drug Dev Ind Pharm; 2011 Sep; 37(9):1100-9. PubMed ID: 21417610
[TBL] [Abstract][Full Text] [Related]
11. Drug targeting strategies for the treatment of inflammatory bowel disease: a mechanistic update.
Dahan A; Amidon GL; Zimmermann EM
Expert Rev Clin Immunol; 2010 Jul; 6(4):543-50. PubMed ID: 20594127
[TBL] [Abstract][Full Text] [Related]
12. [Site-specific drug delivery systems. I. Colon targeted delivery].
Szente V; Zelkó R
Acta Pharm Hung; 2007; 77(3):185-9. PubMed ID: 18019784
[TBL] [Abstract][Full Text] [Related]
13. Multiparticulate formulation approach to colon specific drug delivery: current perspectives.
Asghar LF; Chandran S
J Pharm Pharm Sci; 2006; 9(3):327-38. PubMed ID: 17207416
[TBL] [Abstract][Full Text] [Related]
14. Oral colon delivery: rationale and time-based drug design strategy.
Gazzaniga A; Maroni A; Foppoli A; Palugan L
Discov Med; 2006 Dec; 6(36):223-8. PubMed ID: 17250787
[TBL] [Abstract][Full Text] [Related]
15. Site-specific delivery of anti-inflammatory drugs in the gastrointestinal tract: an in-vitro release model.
Klein S; Stein J; Dressman J
J Pharm Pharmacol; 2005 Jun; 57(6):709-19. PubMed ID: 15969925
[TBL] [Abstract][Full Text] [Related]
16. Cutting-edge technologies in colon-targeted drug delivery systems.
Patel MM
Expert Opin Drug Deliv; 2011 Oct; 8(10):1247-58. PubMed ID: 21933030
[TBL] [Abstract][Full Text] [Related]
17. Exploiting disease-induced changes for targeted oral delivery of biologics and nanomedicines in inflammatory bowel disease.
Zhang Y; Thanou M; Vllasaliu D
Eur J Pharm Biopharm; 2020 Oct; 155():128-138. PubMed ID: 32853696
[TBL] [Abstract][Full Text] [Related]
18. Colon Targeted Rifaximin Nanosuspension for the Treatment of Inflammatory Bowel Disease (IBD).
Kumar J; Newton A
Antiinflamm Antiallergy Agents Med Chem; 2016; 15(2):101-117. PubMed ID: 27449742
[TBL] [Abstract][Full Text] [Related]
19. Regulation of intestinal epithelial function: a link between opportunities for macromolecular drug delivery and inflammatory bowel disease.
Siccardi D; Turner JR; Mrsny RJ
Adv Drug Deliv Rev; 2005 Jan; 57(2):219-35. PubMed ID: 15555739
[TBL] [Abstract][Full Text] [Related]
20. Gut microflora: a new target for therapeutic approaches in inflammatory bowel disease.
Mitsuyama K; Sata M
Expert Opin Ther Targets; 2008 Mar; 12(3):301-12. PubMed ID: 18269340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
